The Nasdaq Composite: Riding the Inertia Surprisingly Dovish FOMC Decision The Nasdaq Composite continues to rise for inertia following the surprisingly dovish FOMC decision where the Fed increased the rate cuts expected in 2024 to three and Fed Chair Powell delivered some dovish comments. The data continues to point to a soft-landing as the latest…
Turkey Introduces Stricter Anti-Money Laundering Regulations for Cryptocurrency Introduction As it became known today, Turkey is introducing stricter anti-money laundering regulations related to cryptocurrency. Starting from Feb. 25, 2025, users who carry out transactions over 15,000 Turkish Liras, equivalent to $425, will be required to provide their identification information to the country’s cryptocurrency service providers….
Discover the Charming World of Kakeibo Budgeting: A Mindful Approach to Money Management Have you ever found yourself at the end of the month, puzzled over your bank statement, wondering where all your money went? You’re not alone. Life’s demands can be overwhelming, and keeping track of finances can feel like a full-time job. But…
The Rise of Spot Bitcoin ETFs BlackRock’s IBIT Bitcoin ETF Leading the Way Since the recent approval of spot Bitcoin exchange-traded funds (ETFs) on January 10, the demand has skyrocketed. BlackRock’s IBIT Bitcoin ETF has emerged as a frontrunner in this new market, achieving impressive milestones in less than two months. This ETF has captured…
Dayforce’s Stock Decline Offers Buying Opportunity The Situation Dayforce’s stock experienced an approximately 8% drop after receiving weak feedback on its 2025 outlook. However, this setback has created a potentially lucrative buying opportunity for investors, as shares are now trading at an appealing price close to $67. Despite a slight slowdown in revenue growth, Dayforce’s…
MERLIN Properties SOCIMI, S.A. (MRPRF) Q4 2024 Results Conference Call On February 28, 2025, at 9:00 AM ET, MERLIN Properties SOCIMI, S.A. (MRPRF) held a conference call to discuss their Q4 2024 financial results. The call was led by Ines Arellano, Director of Investor Relations, Francisco Rivas, Director, and Ismael Clemente, Chief Executive Officer. Participating…
Indaptus Therapeutics’ Decoy20 Receives Clinical Trial Authorization in Canada: Indaptus Therapeutics, a leading biotechnology company, recently announced that it has received Clinical Trial Authorization from Health Canada to initiate clinical trials for its innovative cancer treatment, Decoy20, in Canadian sites. This approval comes as part of the Company’s ongoing clinical trial, INDP-D101, which is currently…
Charmingly Eccentric: The Schall Law Firm Files Class Action Lawsuit Against Metagenomi, Inc. LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Metagenomi, Inc. (“Metagenomi” or “the Company”) (NASDAQ: MGX) for violations of the federal securities…
